Esperion Therapeutics has seen its Fair Value Estimate tick up from $5.80 to $6.10, signaling a modest boost in the company’s assessed intrinsic worth. This adjustment comes as analysts show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback